Skip to main content
Signal8

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

$INCYPress releaseOct 29, 2026, 7:00 AM ETRead the release

Incyte reported Q3 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% year-over-year, driven by growth across its marketed portfolio. Core growth beyond Jakafi was the highlight: Opzelura net sales rose 36% to $255 million and Hematology/Oncology sales rose 38% to $235 million, while flagship Jakafi grew a slower 4% to $827 million. GAAP results swung to a net loss of $3.86 per share due to a one-time $1.23 billion IPR&D charge from the $1.25 billion Vega Therapeutics acquisition; excluding it, operating income grew 18%.

Key figures

Revenue
1557204000
Guidance
FY26 total net sales raised to $5,210-$5,300 million (from $5,130-$5,260 million); Opzelura raised to $1,100-$1,120 million; Hematology and Oncology raised to $890-$910 million; all other categories reaffirmed
Revenue Yoy
14%
Jakafi yoy
4%
Opzelura yoy
36%
Net sales yoy
14%
Total net sales
1316413000
Jakafi net sales
826501000
Vega iprd charge
1230000000
Opzelura net sales
254880000
Hematology oncology yoy
38%
Hematology oncology net sales
235000000
Cash and marketable securities
3854572000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.